CBA TO FDA: Urgent action required on CBD regulation

摘要

The Consumer Brands Association on July 22 renewed its call for government action on cannabidiol (CBD) regulation in letters addressed to Janet Woodcock, MD, acting commissioner of the Food and Drug Administration, and Senator Ron Wyden of Oregon, chairman of the Senate Committee on Finance. The letter to Dr. Woodcock from Betsy Booren, CBA's senior vice president, regulatory affairs, stated the "FDA stance on CBD products is not working" and a regulatory framework for CBD products is "needed now to protect consumers, ensure product safety and transparency, establish guardrails for legal product innovation and distribution in interstate commerce, and provide the clarity needed for manufacturers of these products." Ms. Booren summarized the FDA stance as holding fast to a position that CBD-containing dietary supplements and foods may not be marketed under the exclusionary clauses of the Food, Drug, and Cosmetics Act (FDCA) and that the use of these products may present serious safety concerns.